EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC 4.0

Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study

Zhongsong Zhang iD, Alexander Ploner, Verena Sengpiel, Nestory Kasheshi, Bo Jacobsson, Joakim Dillner, Pär Sparén, Cecilia Kärrberg, Jiayao Lei

BMJ · 2026

DOI: 10.1136/bmj-2026-100739 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift BMJ, 2026. Verfasst von Zhongsong Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden zhongsong.zhang@ki.se. Hauptthemen laut MEDLINE: Pregnancy Outcome, Papillomavirus Infections, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Papillomavirus Vaccines. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the association between quadrivalent human papillomavirus vaccination before pregnancy and subsequent risk of adverse pregnancy outcomes.

Design

Nationwide, population based matched case-control study.

Setting

Population of Sweden, from 1 January 2006 to 31 December 2023.

Participants

624 713 singleton births among nulliparous women aged 16-35 years in Sweden between 2006 and 2023; 92 620 (14.8%) women had received quadrivalent human papillomavirus vaccination before pregnancy. Main outcome measures Risk of adverse pregnancy outcomes associated with quadrivalent human papillomavirus vaccination, with preterm birth (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy OutcomePapillomavirus InfectionsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus VaccinesPregnancy Complications, InfectiousHumansFemalePregnancyCase-Control StudiesSwedenAdultYoung AdultAdolescentPremature BirthInfant, NewbornPremature Rupture of Fetal MembranesHuman Papillomavirus Viruses

Substanzen

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden zhongsong.zhang@ki.se.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Västra Götaland Region, Gothenburg, Sweden.
  • Department of Genetics and Bioinformatics, Area of Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway.
  • Center for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Zhongsong Zhang

Zitieren

APA

Zhang, Z., Ploner, A., Sengpiel, V., Kasheshi, N., Jacobsson, B., Dillner, J., Sparén, P., Kärrberg, C., & Lei, J. (2026). Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study. BMJ. https://doi.org/10.1136/bmj-2026-100739

Vancouver

Zhang Z, Ploner A, Sengpiel V, Kasheshi N, Jacobsson B, Dillner J, et al. Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study. BMJ. 2026. doi:10.1136/bmj-2026-100739

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhongsong and Ploner, Alexander and Sengpiel, Verena and Kasheshi, Nestory and Jacobsson, Bo and Dillner, Joakim and Sparén, Pär and Kärrberg, Cecilia and Lei, Jiayao},
  title = {Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study},
  journal = {BMJ},
  year = {2026},
  doi = {10.1136/bmj-2026-100739}
}
Kostenlos starten →